Cowen & Co. analyst Doug Schenkel reiterated a Hold rating on Genomic Health (NASDAQ: GHDX) today and set a price target of $50. The company’s shares opened today at $56.72, close to its 52-week high of $59.49.
According to TipRanks.com, Schenkel is a 5-star analyst with an average return of 22.3% and a 71.8% success rate. Schenkel covers the Healthcare sector, focusing on stocks such as Becton Dickinson, Myriad Genetics, and NanoString Tech.
The word on The Street in general, suggests a Hold analyst consensus rating for Genomic Health with a $51.08 average price target, implying a -9.9% downside from current levels. In a report issued on July 27, Piper Jaffray also maintained a Hold rating on the stock with a $50 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $59.49 and a one-year low of $26.54. Currently, Genomic Health has an average volume of 311.6K.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GHDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genomic Health, Inc. provides genomic-based diagnostic tests, which analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. It uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning.
